Eye Therapies, LLC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

Brimonidine Tartrate 0.025% · Ophthalmology
Brimonidine tartrate is an alpha-2 adrenergic agonist that reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Phase 2 pipeline

Brimonidine Tartrate 0.01%
Oxymetazoline HCl 0.025%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Eye Therapies, LLC portfolio CI brief
Eye Therapies, LLC pipeline updates RSS

Frequently asked questions about Eye Therapies, LLC

What is Eye Therapies, LLC's pipeline?

Eye Therapies, LLC has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Brimonidine Tartrate 0.025%.

Sector hub: All tracked pharma companies